Oncology Pharma Announces the Appointment Of New Chief Economical Officer

San Francisco, CA, Jan. 28, 2021 (World NEWSWIRE) — by using NewMediaWire — Oncology Pharma Inc. (OTC: ONPH) is pleased to announce that it has retained the expert services of Mr. James Smith, CPA as its new Chief Economical Officer.  

Mr. James Smith, CPA is a seasoned govt officer with practical experience encompassing various community and private companies across a wide range of industries.  His prior encounter consists of CEO and/or CFO in two absolutely reporting SEC registrants as nicely as numerous OTC Pink Sheet corporations in either the CFO, outside the house accountant or CEO capacities. In addition, for the duration of his employment with two nationwide accounting companies and in his very own CPA firm apply, Mr. Smith has labored with numerous Family Places of work and investors in helping them with their functions, money placement, organizational technique and framework, with an emphasis on tax and estate scheduling.  

“I pretty a great deal appear ahead to assisting the Oncology Pharma staff as we even more progress the advancement and commercialization of many superb biotechnology alternatives. There appears to be like to be a whole lot of prospective for the suite of systems assembled by the workforce and it is remarkable to be a portion of the energy to provide to fruition the application of individuals systems to serious planet methods to professional medical troubles,” claimed Mr. Smith in response to his appointment.

Oncology Pharma is happy to welcome Mr. Smith aboard as the Firm is doing work in direction of increasing its portfolio and financing.


ONCOLOGY PHARMA, INC. (OTCPK: ONPH) (the “Company”) is now participating in investigation and enhancement of therapeutics for oncology and prides by itself for possessing a earth-course Advisory Board that keeps the Organization in the forefront of developing technologies in cancer exploration, biotechnology, and health care.

Ahead Hunting STATEMENTS

Selected of the matters talked over in this announcement consist of ahead-seeking statements that include materials risks to and uncertainties in the Company’s organization that may well lead to true outcomes to differ materially from individuals expected by the statements built herein. Such risks and uncertainties contain dangers similar to licensing arrangements and joint ventures, which includes the need to have to negotiate the definitive agreements for the associations achievable failure to realize anticipated positive aspects of enterprise associations and, expenses of giving funding to these company interactions. Other risks and uncertainties relating to the Enterprise incorporate, amid other things, current destructive operating dollars flows and a need to have for further funding to finance our working approach the conditions of any further financing, which may be extremely dilutive and may well consist of onerous phrases unexpected prices and functioning deficits, and lower than predicted revenue and revenues uncertain willingness and capacity of clients to undertake new systems and other things that may perhaps have an impact on even more market place acceptance adverse economic circumstances adverse final results of any lawful proceedings the volatility of our functioning benefits and economical situation incapability to attract or keep certified senior management personnel, which includes sales and marketing personnel our potential to build and keep the proprietary mother nature of our technological know-how as a result of the patent method, as properly as our skill to possibly license from other individuals patents and patent programs vital to build products the Company’s capability to put into practice its very long selection organization program for various apps of its know-how the Company’s ability to enter into agreements with any important marketing and advertising and/or distribution partners and with any strategic or joint undertaking partners the impact of competitiveness the acquiring and upkeep of any important regulatory clearances applicable to apps of the Company’s technologies management of progress and, other risks and uncertainties. This is not a solicitation to buy or market securities and does not purport to be an investigation of the Company’s financial place.

For supplemental info, you should get in touch with the Oncology Pharma at:

1 Sansome Road, Suite 3500

San Francisco, CA 94104

Cellphone: 415-869-1038

Fax: 415-946-8801 

E mail: [email protected]